>> Pascal Biosciences appoints Shepard as director << 2020-07-09 10:53 ET - News Release
Dr. Patrick Gray reports
PASCAL BIOSCIENCES APPOINTS DR. MICHAEL SHEPARD TO BOARD OF DIRECTORS
Pascal Biosciences Inc. has appointed Dr. H. Michael Shepard to its board of directors.
Dr. Shepard was a 2019 recipient of the Lasker Award for medical research and public service, conferred for his role in the discovery and development of the drug Herceptin (trastuzumab). The Lasker Awards are regarded as America's top biomedical research prize, and approximately 90 past recipients have proceeded to win a Nobel Prize. Herceptin treats breast cancer patients with HER2-positive tumours, marking an especially aggressive form of the disease. Over two million patients have benefited from this discovery.
"Mike is a great addition to our board. He is a world expert in cancer and immunology and also has 40 years of experience in the biotech industry," said Dr. Patrick Gray, chief executive officer of Pascal. "We are very pleased to welcome Mike, as his expertise will guide our discovery and development efforts. His direction will create significant value for our shareholders".
Dr. Shepard started his career in biotechnology at Genentech where he discovered Herceptin. He subsequently initiated several successful biotech companies and then served as vice-president and chief scientific officer of Halozyme Therapeutics. In 2007, he was awarded the prestigious Warren Alpert Prize from Harvard Medical School and the Warren Alpert Foundation. Dr. Shepard is an author on over 90 peer-reviewed publications and has been an inventor of more than 50 patents. Dr. Shepard received his BS degree from the University of California, Davis, and his PhD from the University of Indiana.
About Pascal Biosciences Inc.
Pascal is a biotechnology company targeting innovative therapies for serious diseases, including COVID-19. Pascal is also developing treatments for cancer with targeted therapies for acute lymphoblastic leukemia and cannabinoid-based therapeutics.